Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Lung fibrosis involves the overexpression of ECM proteins, primarily collagen, by α-smooth muscle actin (ASMA)-positive cells. Caveolin-1 is a master regulator of collagen expression by cultured lung fibroblasts and of lung fibrosis in vivo. A peptide equivalent to the caveolin-1 scaffolding domain (CSD peptide) inhibits collagen and tenascin-C expression by normal lung fibroblasts (NLF) and fibroblasts from the fibrotic lungs of scleroderma patients (SLF). CSD peptide inhibits ASMA expression in SLF but not NLF. Similar inhibition of collagen, tenascin-C, and ASMA expression was also observed when caveolin-1 expression was upregulated using adenovirus. These observations suggest that the low caveolin-1 levels in SLF cause their overexpression of collagen, tenascin-C, and ASMA. In mechanistic studies, MEK, ERK, JNK, and Akt were hyperactivated in SLF, and CSD peptide inhibited their activation and altered their subcellular localization. These studies and experiments using kinase inhibitors suggest many differences between NLF and SLF in signaling cascades. To validate these data, we determined that the alterations in signaling molecule activation observed in SLF also occur in fibrotic lung tissue from scleroderma patients and in mice with bleomycin-induced lung fibrosis. Finally, we demonstrated that systemic administration of CSD peptide to bleomycin-treated mice blocks epithelial cell apoptosis, inflammatory cell infiltration, and changes in tissue morphology as well as signaling molecule activation and collagen, tenascin-C, and ASMA expression associated with lung fibrosis. CSD peptide may be a prototype for novel treatments for human lung fibrosis that act, in part, by inhibiting the expression of ASMA and ECM proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis
Wang, X. M., Zhang, Y., Kim, H. P., Zhou, Z., Feghali-Bostwick, C. A., Liu, F., Ifedigbo, E., Xu, X., Oury, T. D., Kaminski, N., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061536 · Cited by 397
Distinction between signaling mechanisms in lipid rafts vs. caveolae
Sowa, G., Pypaert, M., & Sessa, W. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241409998 · Cited by 233
Self-citation
Cited by
Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease
Gourdie, R. G., Dimmeler, S., & Kohl, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.89 · Cited by 332
Transforming growth factor β as a therapeutic target in systemic sclerosis
Varga, J., & Pasche, B. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.26 · Cited by 295
Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic Diseases
Piera-Velazquez, S., Mendoza, F., & Jimenez, S. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5040045 · Cited by 273
Vascular involvement in systemic sclerosis (scleroderma)
Postlethwaite, Pattanaik, D., & Brown, M. (2011) · Journal of Inflammation Research · doi:10.2147/jir.s18145 · Cited by 119
Tourkina, E., Bonner, M., Oates, J., Hofbauer, A., Richard, M., Znoyko, S., Visconti, R. P., Zhang, J., Hatfield, C. M., Silver, R. M., et al. (2011) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-4-15 · Cited by 104
Self-citation
Metadata
- Authors
- Tourkina, E., Richard, M., Gööz, P., Bonner, M., Pannu, J., Harley, R., Bernatchez, P. N., Sessa, W. C., Silver, R. M., & Hoffman, S.
- Venue
- American Journal of Physiology-Lung Cellular and Molecular Physiology
- Publisher
- American Physiological Society
- Published
- 2008-05
- Volume
- 294
- Issue
- 5
- Pages
- L843-L861
- ISSN
- 1040-0605 (ISSN-L)
- 1522-1504
- OpenAlex
- W2130704025
- Cited by
- 152
- References
- 2
- FWCI
- 9.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.